

RESEARCH

Open Access



Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study

Maryse C. Cnossen^{1*}, Jilske A. Huijben¹, Mathieu van der Jagt², Victor Volovici^{1,3}, Thomas van Essen⁴, Suzanne Polinder¹, David Nelson⁵, Ari Ercole⁶, Nino Stocchetti^{7,8}, Giuseppe Citerio^{9,10}, Wilco C. Peul^{4,11}, Andrew I. R. Maas¹², David Menon⁶, Ewout W. Steyerberg^{1,13}, Hester F. Lingsma¹ on behalf of the CENTER-TBI investigators

Abstract

Background: No definitive evidence exists on how intracranial hypertension should be treated in patients with traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients with TBI.

Methods: A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study.

Results: The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals ($n = 60$, 91%) and designated level I trauma centers ($n = 44$, 67%). The Brain Trauma Foundation guidelines were used in 49 (74%) centers. Approximately 90% of the participants ($n = 58$) indicated placing an ICP monitor in patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications or on peri-insertion precautions. We found wide variation in the use of first- and second-tier treatments for elevated ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and treatment ($n = 32$, 48%), whereas the others were considered more conservative ($n = 34$, 52%).

Conclusions: Substantial variation was found regarding monitoring and treatment policies in patients with TBI and intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma centers and provide an opportunity and necessity for comparative effectiveness research.

Keywords: Traumatic brain injury, Intracranial hypertension, ICP, ICU, Comparative effectiveness research, Survey

* Correspondence: m.c.cnossen@erasmusmc.nl

¹Center for Medical Decision Making, Department of Public Health, Erasmus MC, Rotterdam, The Netherlands

Full list of author information is available at the end of the article



Background

Secondary brain injury associated with elevated intracranial pressure (ICP) is an important cause of mortality and morbidity in patients with severe traumatic brain injury (TBI) [1]. Therefore, identifying high ICP and optimizing its management is believed to be critically important. Yet, no definitive evidence exists on how ICP should be monitored and treated [2]. Patient and treatment heterogeneity make conducting randomized controlled trials (RCTs) challenging. On one hand, the majority of RCTs done to date have produced nonsignificant findings [3]. On the other hand, observational studies, which are easier to conduct, are at risk for confounding by indication, hampering causal inference [4, 5].

In the absence of conclusive evidence, treatment policy is usually based on local practices, individual preferences, and resource availability [6–9]. It is likely that centers and practitioners individually balance potential benefits and risks of different ICP management strategies, which may result in some centers being relatively aggressive and others being more conservative in their treatment policies.

A novel and promising approach in estimating treatment effectiveness is to exploit the existing variation by comparing standard practices between different centers or countries, which is referred to as comparative effectiveness research (CER) [10, 11]. The Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study (grant 602150) is currently recruiting and will use CER methodology to study treatment effectiveness of ICP management [10]. As a first step, we examined self-perceived practices of ICP monitoring and associated treatment policies by sending a survey to the centers participating in the CENTER-TBI study. Because previous European survey studies that addressed ICP management were published more than 10 years ago [12, 13], this study will provide an up-to-date overview of ICP management in Europe. Topics identified as showing substantial between-center variation that are plausibly associated with patient outcome will be selected for CER, and their treatment effectiveness can be studied once the CENTER-TBI patient-level data become available.

Methods

Study sample

All centers participating in the prospective, longitudinal, observational CENTER-TBI study (<https://www.center-tbi.eu/>) were asked to complete a set of questionnaires on structures and processes of care for patients with TBI. Questionnaires were sent to 71 centers in 20 countries between 2014 and 2015 [14]. Three centers dropped out of the CENTER-TBI study, resulting in 68 eligible centers from Austria ($n = 2$), Belgium ($n = 4$), Bosnia and Herzegovina ($n = 2$), Denmark ($n = 2$), Finland ($n = 2$),

France ($n = 7$), Germany ($n = 4$), Hungary ($n = 2$), Israel ($n = 2$), Italy ($n = 9$), Lithuania ($n = 2$), Latvia ($n = 3$), The Netherlands ($n = 7$), Norway ($n = 2$), Romania ($n = 1$), Serbia ($n = 1$), Spain ($n = 4$), Sweden ($n = 2$), the United Kingdom ($n = 9$), and Switzerland ($n = 1$).

Questionnaire development and administration

A set of questionnaires designed to measure structure and process of TBI care was developed on the basis of available literature and expert opinion. These questionnaires were comprehensively described in a previous publication [14]. Pilot testing was undertaken in 16 of the participating centers, and feedback was incorporated into the final questionnaire design.

One of the questionnaires contained 29 questions on ICP monitoring and treatment at the intensive care unit (ICU) (Additional file 1). In most questions, we explicitly asked for the “general policy,” which was defined as the treatment or monitoring modality estimated to be used in more than 75% of patients, recognizing that there might be exceptions. In some questions, we asked for quantitative estimations. The representatives of the centers could indicate how often they used a particular monitoring or treatment strategy (never = 0–10%, rarely = 10–30%, sometimes = 30–70%, frequently = 70–90%, always = 90–100%). The options “frequently” and “always” were interpreted as representing the general policy, in line with a previous report [15]. All definitions used in the questionnaire are described in Additional file 2.

Analyses

We calculated frequencies and percentages for all variables related to the number of responders for that variable. We examined factors associated with a relatively aggressive ICP monitoring and treatment strategy with the chi-square test or Fisher’s exact test as appropriate. Centers were classified as being relatively aggressive if they (a) place an ICP monitor in patients with a Glasgow Coma Scale (GCS) score ≤ 8 and an abnormal head computed tomographic (CT) scan, and (b) if they generally perform at least one of three second-tier treatments that represent a maximum therapy intensity (barbiturates, decompressive craniectomy, and hypothermia $< 35^\circ\text{C}$) [16].

We examined whether there were differences between and within geographic regions in the use of first- and second-tier treatments. Countries were divided into seven geographic regions (Northern Europe, Western Europe, United Kingdom, Southern Europe, Eastern Europe, Baltic states, and Israel). Within each region, we examined the percentage of centers which indicated that the particular treatment was their general policy. In addition, we assessed the influence of geographic region on treatment decision by performing logistic regression analysis with treatment as the dependent variable (general

policy yes/no) and geographic region (categorical variable) as an independent variable. The Nagelkerke R^2 was reported, representing the proportion of variation in treatment that can be explained by geographic region. Analyses were performed using IBM SPSS Statistics version 21 software [17].

Results

Participating centers

Sixty-six centers (97% response rate) completed the questionnaire on ICP monitoring and treatment in patients with severe TBI. Questionnaires were completed mainly by intensive care physicians ($n = 33, 50\%$) and neurosurgeons ($n = 23, 35\%$). Most centers ($n = 60, 91\%$) had an academic affiliation, and 44 (67%) were designated level I trauma centers (see Additional file 2 for definitions). Centers had a median of 33 (IQR 22–44) ICU beds in total and treated a median of 92 (IQR 52–160) patients with severe TBI annually. Forty-three (65%) centers had adopted a “closed” ICU model, which is defined as an ICU model where a critical care physician (intensivist) is primarily responsible for the delivery of care for patients at the ICU [18]. An “open” model, defined as an ICU model where the admitting physician (e.g., neurosurgeon) is primarily responsible for the care of ICU patients, was adopted in three (5%) centers [18]. A “mixed” model, which is an ICU model where the

admitting physician is primarily responsible but the care is provided by a critical care physician, was adopted in 20 (30%) centers. Approximately half ($n = 39$) of the centers had a dedicated neurosciences ICU. Approximately three-fourths of sites ($n = 49, 74\%$) indicated that they used the 2007 Brain Trauma Foundation (BTF) guidelines or institutional guidelines that were based on the BTF guidelines.

Indications for ICP monitoring

The majority of participants ($n = 58, 91\%$) indicated that they would generally place an ICP monitor in patients with $GCS \leq 8$ and CT abnormalities (Fig. 1). ICP monitors were less often considered for other indications, such as $GCS \leq 8$ without CT abnormalities ($n = 15, 23\%$), inability to assess a patient with CT abnormalities clinically (e.g., due to sedatives; $n = 11, 17\%$), and intraventricular hemorrhage ($n = 21, 33\%$). Around one-third of the participants would place an ICP monitor in patients with polytrauma ($GCS > 8$) who require extracranial surgery or mechanical ventilation but would not otherwise have an indication for ICP monitoring. Patient-specific reasons for not monitoring ICP included when the risk of raised ICP was considered low ($n = 40, 62\%$), patients were considered unsalvageable ($n = 37, 57\%$), or GCS was > 8 ($n = 37, 57\%$) (Additional file 2).




Fig. 1 Indications for ICP monitoring placement. Shown are the percentages of centers that indicated that they would generally place an ICP monitor in patients with the described characteristics. Question was completed by 64 of 66 centers. CT Computed tomographic, GCS Glasgow Coma Scale, ICP Intracranial pressure

Variability in monitoring and treatment of intracranial hypertension

There is large variation in monitoring and treatment characteristics among European centers treating patients with TBI (Fig. 2a and b).

Parenchymal and ventricular ICP devices

Both parenchymal and ventricular ICP devices were available in more than half of centers ($n = 38$, 59%). One-third ($n = 21$) of the participants indicated that they used only parenchymal monitors, whereas five (8%) participants indicated that they used only ventricular catheters. In centers that used both types of monitors, parenchymal monitors were typically used routinely, with ventricular catheters placed either when the ventricles were enlarged or when cerebrospinal fluid (CSF) drainage was indicated. When a ventricular drain was used, half of the participants indicated that their local practice was generally to leave the drain open ($n = 19$, 50%), and the other half indicated a policy of intermittent drainage ($n = 19$, 50%) (Fig. 2a).

Precautions with ICP monitor placement

Half of the participants (55% ventricular catheter and 43% parenchymal sensor) indicated that they generally administered prophylactic antibiotics prior to the insertion of an ICP monitor, which was continued in around 10% of the centers. The majority of participants ($n = 50$, 77%) generally assessed the patient's coagulation status prior to ICP monitor insertion. There was wide variability regarding the minimum international normalized ratio and minimum platelet count considered safe for device insertion (Fig. 2a).

Additional neuromonitoring

Half of the participants ($n = 33$) indicated that they generally used at least one additional neuromonitoring device (Additional file 2). Transcranial Doppler was generally applied in 24 (38%) centers, and brain tissue oxygenation was used in 12 (19%) centers.

First-tier treatment of elevated ICP

The majority of participants indicated an ICP threshold for medical treatment > 20 mmHg ($n = 54$, 83%) (Fig. 2b). There was less consensus on cerebral perfusion pressure (CPP) treatment thresholds; 39 participants (59%) indicated a threshold of 60 mmHg in their center, whereas 25 (38%) indicated individualized CPP targets.

Propofol ($n = 54$, 83%), midazolam ($n = 48$, 75%), fentanyl ($n = 37$, 58%), and morphine ($n = 32$, 51%) were generally used as part of first-tier treatment in patients with elevated ICP, whereas the use of α_2 -agonists ($n = 10$, 16%) and barbiturates ($n = 12$, 19%) was less frequent

(Fig. 2b and Additional file 2). Neuromuscular blocking agents were generally used in 16 (25%) centers. Participants typically preferred a specific combination of sedatives and analgesics as part of first-tier treatments: 50 participants (76%) indicated they used two to four of eight sedatives and analgesics as general policy and the other interventions only infrequently (Additional file 2).


Regarding the use of osmotic therapy, two-thirds of the participants indicated generally using mannitol ($n = 43$, 65%) and/or hypertonic saline ($n = 44$, 67%). Seventeen participants indicated the use of mannitol, but not hypertonic saline, as their general policy, whereas 18 participants indicated the opposite. Fourteen (22%) participants indicated generally using hypertonic saline in conjunction with mannitol (Fig. 2b). Crystalloids were the most commonly used intravenous fluids to augment CPP ($n = 60$, 91%), whereas other fluids (starches, albumin, and other combinations) were less often used (12–23%). Vasopressors were generally used in almost all centers to support CPP ($n = 63$, 96%). Among the parameters used to titrate vasoactive drugs, mean arterial pressure targets ($n = 51$, 77%) and transpulmonary thermodilution monitoring by means of pulse contour cardiac output ($n = 35$, 53%) were most often used (Additional file 2).

Second-tier treatments for refractory intracranial hypertension

Among the second-tier treatments, decompressive craniectomy ($n = 26$, 39%), barbiturates ($n = 21$, 32%), and CSF drainage ($n = 22$, 33%) were the most often employed (Fig. 2b). Hypothermia and hyperventilation (partial pressure of carbon dioxide < 30 mmHg) were the general policy in 24.6% and 15.4% of the centers, respectively, whereas approximately one-third of the participants indicated never using hypothermia and hyperventilation (Additional file 2). Participants typically preferred one ($n = 27$, 42%) or two ($n = 20$, 31%) second-tier treatments and indicated use of the other options infrequently (Additional file 2). Details on indication, administration, and targets of second-tier treatments are presented in Additional file 2 and show a high degree of variability.

Factors associated with aggressive monitoring and treatment policies

Around half of the centers were classified as using an aggressive ICP monitoring and treatment policy ($n = 32$, 48%). Centers with an open or mixed ICU model more often applied an aggressive ICP management style in comparison to centers with a closed ICU model ($p = 0.05$). We did not find significant associations between aggressiveness and any of the other factors studied (Table 1).



(See figure on previous page.)

Fig. 2 a Algorithm for ICP management: ICP monitoring. The *blue box* represents ICP monitoring with the policy of parenchymal monitor on the left and ventricular catheter on the right. *Orange boxes* are checkpoints during the ICP monitoring process. The *N* value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. ¹ Centers that indicated these situations as the top one of the top three reasons for choosing a ventricular or parenchymal catheter. ² Frequently and always summed. ³ Arterial blood pressure, midauricular level, ventricular motor, not applicable (we use only parenchymal monitors), room air, calibrated by device and meatus externa. ⁴ Prior to insertion of ventricular catheter for ICP monitoring. ⁵ Depending on other factors, such as the use of platelet aggregation inhibitors. ⁶ Multiplate and rotational thromboelastometric analysis prior to surgery if concerns. **b** Algorithm for ICP management: treatment indications, first- and second-tier treatment. The *red box* represents ICP treatment with first-tier treatment on *top* and second-tier treatment at the *bottom*. *Orange boxes* are checkpoints during the ICP treatment process. The *N* value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. ¹ Decompressive craniectomy is (almost) never performed in our hospital. ² Multiple answers were possible. ³ Only if ventricles are enlarged. ⁴ Frequently and always summed. ⁵ Clonidine or dexmedetomidine. ⁶ Sufentanil (4), remifentanil (2), β -blockers (1), alfentanil (2), esketamine (1). ⁷ Standard continuous infusion. ⁸ $\text{PaCO}_2 < 30$ mmHg. ⁹ Variable, depends on patient. ¹⁰ Variable, depends on physician. *CPP* Cerebral perfusion pressure, *CSF* Cerebrospinal fluid, *EEG* Electroencephalogram, *HS* Hypertonic saline, *ICP* Intracranial pressure, *INR* International normalized ratio, *IV* Intravenous, *PaCO₂* Partial pressure of carbon dioxide

Influence of geographic region on treatment decisions

The use of first- and second-tier treatments varied substantially within and between geographic regions (Table 2). Morphine and CSF drainage showed the largest within-region variation, with approximately half of the participants within each region stating they generally use these treatments. Between-region differences were especially pronounced for barbiturates as first-tier treatment. Barbiturates were used mainly in the Baltic states and Eastern Europe, and geographic region explained 63% of the variance in barbiturate use. In addition, the use of mannitol varied substantially across regions, with all participants in the Baltic states, Eastern Europe, and Israel indicating they generally use mannitol, whereas only 11% of the participants in Northern Europe stated they generally use mannitol. In Northern Europe, Western Europe, and the United Kingdom, propofol, midazolam, morphine, and hypertonic saline are generally applied as first-tier treatment, whereas participants in Southern Europe, the Baltic states, and Eastern Europe also indicated they generally use fentanyl, barbiturates, CSF drainage, and mannitol.

Discussion

We found substantial variation in the general approaches to ICP monitoring and treatment among 66 European neurotrauma centers. The majority of centers indicated that they would insert an ICP monitor in patients with severe TBI and head CT abnormalities. There was no consensus on other indications, however, nor was there consensus on peri-insertion precautions. The use of both first- and second-tier treatments for elevated ICP varied widely between centers and regions. We found that half of the centers employed a relatively aggressive ICP management approach, and the other half reported using a more conservative approach.

Strengths of this study include the high response rate (97%), the extensive development process of the questionnaire, and the comprehensive examination of both

monitoring and treatment. In addition, because our survey was completed by centers that are currently collecting patient-level data for the CENTER-TBI study, the results of this study can be used directly as input for the CER analyses once the patient-level data become available. A limitation of our study is that the included centers represent a select group of European neurotrauma centers that are prominent in the field of neurotrauma care and research. Consequently, the picture obtained might be skewed. In addition, this study is dependent on perceived practices rather than on clinical data. Although we repeatedly emphasized confidentiality of results, we cannot exclude that some physicians presented (even subconsciously) a more favorable image or presented individual treatment preferences rather than the general policy in a center. This can be explored when individual patient-level data are available. A further limitation is that we asked for isolated general treatments but did not assess specific combinations. In clinical practice, however, different treatments are used simultaneously, and outcome might be determined by the combination of treatments provided rather than by one particular intervention.

The substantial variation in strategies for ICP management in our study was in line with previous survey studies in Europe [12, 13] and the United States [15]. For example, Hesdorffer et al. [15] found that mannitol, hypertonic saline, and hyperventilation were generally used in half of their centers. Guidelines have been proposed to reduce treatment variation in medicine [19]. Although there has been an increase in protocolization of medicine and awareness of guidelines during the last decade, variation in ICP management may not have been reduced [12, 13]. Moreover, some participants claimed using treatments that are discouraged in the BTF guidelines. For example, one-fifth of the participants specified using barbiturates as first-tier treatment, whereas this is a second-tier treatment in the BTF guidelines [20]. The discrepancy between BTF guidelines and reported policies indicates that there is little

Table 1 Factors associated with an aggressive ICP management style

Factor	Relatively aggressive centers (n = 32)	Relatively conservative centers (n = 34)	p Value
ICU organization			0.05
Closed	17 (40%)	26 (60%)	
Open/mixed	15 (65%)	8 (35%)	
Dedicated neurosciences ICU			0.96
Available	19 (49%)	20 (51%)	
Not available	13 (48%)	14 (52%)	
BTF guidelines used ^a			0.48
Yes	25 (51%)	24 (49%)	
No	7 (41%)	10 (59%)	
Volume ^b			0.82
High volume	17 (47%)	19 (53%)	
Low volume	15 (50%)	15 (50%)	
Country's income level ^c			0.83
High income	27 (49%)	28 (51%)	
Relatively low income	5 (46%)	6 (54%)	
Geographic location ^d			0.84
Northern Europe	4 (44%)	5 (56%)	
Western Europe	13 (52%)	15 (48%)	
United Kingdom	3 (43%)	4 (57%)	
Southern Europe	5 (42%)	7 (58%)	
Baltic states	2 (40%)	3 (60%)	
Eastern Europe	3 (50%)	3 (50%)	
Israel	2 (100%)	0 (0%)	

BTF Brain Trauma Foundation, **ICU** Intensive care unit

^a BTF guidelines or institutional guidelines that were broadly based on the BTF guidelines

^b Relatively high volume (number of patients with severe TBI admitted to the ICU higher than the median number of patients with severe TBI admitted to the ICU [n = 92]) vs. relatively low volume (number of patients with severe TBI admitted to the ICU lower than or equal to the median number of patients with severe TBI admitted to the ICU)

^c The division into relatively high- and low-income countries was based on a 2007 report by the European Union [21]. High income = Austria, Belgium, Denmark, Finland, France, Germany, Israel, Italy, The Netherlands, Norway, Spain, Sweden, United Kingdom, and Switzerland; relatively low income = Bosnia and Herzegovina, Bulgaria, Hungary, Latvia, Lithuania, Romania, and Serbia

^d Northern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania

consensus among neurotrauma centers with respect to ICP management. This might be due to the relatively small evidence base underpinning the guidelines [3].

Our study has several implications for the planned CER analyses. We found wide variation for most of the topics studied, which enables analyzing effectiveness of ICP management at the hospital level. Analyzing effectiveness at the hospital level might be especially useful for treatments that were indicated to be used “rarely,” “sometimes,” or “frequently” by the large majority of participants. For these treatments, patient characteristics play an important role, and these can dramatically confound conventional patient-level analyses [4, 5]. Caution should be applied, however, in the interpretation of the effects of treatments that are performed solely in some

regions and not in others. For example, barbiturates are often used as first-tier treatment in the Baltic states and Eastern Europe but not in other regions. A harmful or beneficial effect could therefore also be attributed to other aspects of care in the particular regions rather than to barbiturate use itself. In principle, it is possible to adjust statistically for between-center differences other than the treatment variable of interest with a random-effects model with a random intercept for center. However, when correlations between the treatment variable of interest and other factors that differ between centers are strong, such as for the first-line use of barbiturates and region, this might not be sufficiently captured by the random-effects model. In such a case, differences in outcome cannot be attributed with certainty to the treatment under study.

Table 2 Within- and between-region variation in first- and second-tier treatments for elevated intracranial pressure

Variable	Northern Europe (n =9)	Western Europe (n = 25)	United Kingdom (n =7)	Southern Europe (N =12)	Baltic states (n = 5)	Eastern Europe (n = 6)	Israel (n = 2)	Nagelkerke R ² value
First-tier treatments								
Propofol	78%	76%	100%	92%	80%	67%	100%	0.14
Midazolam	67%	76%	29%	75%	100%	83%	100%	0.22
Fentanyl	44%	44%	29%	67%	100%	100%	50%	0.31
Morphine	56%	48%	57%	50%	40%	33%	50%	0.02
Neuromuscular blocking agents	0%	16%	29%	25%	40%	67%	50%	0.25
α ₂ -Agonists	33%	12%	0%	17%	40%	0%	0%	0.22
Barbiturates	11%	8%	0%	0%	80%	83%	0%	0.63
CSF drainage	33%	24%	0%	25%	60%	50%	0%	0.20
Mannitol	11%	67%	43%	83%	100%	100%	100%	0.46
Hypertonic saline	89%	71%	86%	58%	40%	33%	100%	0.20
Second-tier treatments								
Decompressive craniectomy	33%	36%	29%	33%	80%	33%	100%	0.16
Hypothermia	22%	25%	71%	25%	0%	0%	0%	0.29
Deep hyperventilation	0%	13%	0%	33%	20%	33%	0%	0.24
Barbiturates	11%	29%	14%	33%	80%	67%	0%	0.25
CSF drainage	56%	28%	43%	33%	20%	17%	50%	0.08

CSF Cerebrospinal fluid

Note. Table presents the percentage of participants within each geographic region that indicated that the first- or second-tier treatment was their general policy. Nagelkerke R² was derived from a logistic regression analysis with treatment (general policy yes/no) as the dependent variable and geographic region (categorical variable) as an independent variable. Nagelkerke R² represents the proportion of variance of the treatment variable that is accounted for by geographic region Northern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania

On the basis of our findings, we recommend prioritizing the following topics for CER because of the feasibility of the center-level approach:

1. ICP monitoring in patients with indications other than GCS ≤ 8 and CT abnormalities
2. Parenchymal vs. ventricular monitoring (with and without CSF drainage)
3. Use of first-tier treatments for elevated ICP (including use of neuromuscular blocking agents, mannitol vs. hypertonic saline vs. mannitol + hypertonic saline, fentanyl vs. no fentanyl, fluid management)
4. Use of second-tier treatments (including decompressive craniectomy vs. barbiturates vs. hypothermia)
5. The effect of an aggressive ICP management policy vs. a more conservative approach

Conclusions

Substantial variation was found in the monitoring and treatment of patients with severe TBI and intracranial hypertension. These results indicate a lack of consensus among European neurotrauma centers and provide an important opportunity and necessity for CER to support the development of optimal treatment protocols for these severely affected patients.

Additional files

Additional file 1: Provider profiling questionnaire. (PDF 672 kb)

Additional file 2: Detailed results. (PDF 85 kb)

Abbreviations

BTF: Brain Trauma Foundation; CENTER-TBI: Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury; CER: Comparative effectiveness research; CPP: Cerebral perfusion pressure; CSF: Cerebrospinal fluid; CT: Computed tomographic; EEG: Electroencephalogram; GCS: Glasgow Coma Scale; HS: Hypertonic saline; ICP: Intracranial pressure; ICU: Intensive care unit; INR: International normalized ratio; IV: Intravenous; PaCO₂: Partial pressure of carbon dioxide; RCT: Randomized controlled trial; TBI: Traumatic brain injury

Acknowledgements

The authors thank all clinical staff and researchers at the CENTER-TBI sites for completing the provider profiling questionnaires.

CENTER-TBI investigators and participants

Hadie Adams¹, Masala Alessandro², Judith Allanson³, Krisztina Amrein⁴, Norberto Andaluz⁵, Nada Andelic⁶, Nanni Andrea², Lasse Andreassen⁷, Audny Anke⁸, Anna Antoni⁹, Hilko Ardon¹⁰, Gérard Audibert¹¹, Kaspars Auslands¹², Philippe Azouvi¹³, Camelia Baciu¹⁴, Andrew Bacon¹⁵, Rafael Badenes¹⁶, Trevor Baglin¹⁷, Ronald Bartels¹⁸, Pál Barzó¹⁹, Ursula Bauerfeind²⁰, Ronny Beer²¹, Francisco Javier Belda¹⁶, Bo-Michael Bellander²², Antonio Belli²³, Rémy Bellier²⁴, Habib Benali²⁵, Thierry Benard²⁴, Maurizio Berardino²⁶, Luigi Beretta²⁷, Christopher Beynon²⁸, Federico Bilotta¹⁶, Harald Binder⁹, Erta Biqiri¹⁴, Morten Blaabjerg²⁹, Stine Borgen Lund³⁰, Pierre Bouzat³¹, Peter Bragge³², Alexandra Brazinova³³, Felix Brehar³⁴, Camilla Brorsson³⁵, Andras Buki³⁶, Monika Bullinger³⁷, Veronika Bučková³³, Emiliana Calappi³⁸, Peter Cameron³⁹, Lozano Guillermo Carbayo⁴⁰, Elsa Carise²⁴, Keri Carpenter⁴¹, Ana M. Castaño-León⁴², Francesco Causin⁴³, Giorgio Chevillard¹⁴,

Arturo Chieragato¹⁴, Giuseppe Citerio^{44, 45}, Maryse Cnossen⁴⁶, Mark Coburn⁴⁷, Jonathan Coles⁴⁸, Jamie D. Cooper⁴⁹, Marta Correia⁵⁰, Amra Covic⁵¹, Nicola Curry⁵², Endre Czeiter⁵³, Marek Czosnyka⁵⁴, Claire Dahyot-Fizelier²⁴, François Damas⁵⁵, Pierre Damas⁵⁶, Helen Dawes⁵⁷, Véronique De Keyser⁵⁷, Francesco Della Corte⁵⁹, Bart Depreitere⁶⁰, Shenghao Ding⁶¹, Diederik Dippel⁶², Kemal Dizdarevic⁶³, Guy-Loup Dulière⁵⁵, Adelaida Dzeko⁶⁴, George Eapen¹⁵, Heiko Engemann⁵¹, Ari Ercole⁵⁵, Patrick Esser⁵⁷, Erzsébet Ezer⁶⁶, Martin Fabricius⁶⁷, Valery L. Feigin⁶⁸, Junfeng Feng⁶¹, Kelly Foks⁶², Francesca Fossi¹⁴, Gilles Francony³¹, Janek Frantzen⁶⁹, Ulderico Freo⁷⁰, Shirin Frisvold⁷¹, Alex Furmanov⁷², Pablo Gagliardo⁷³, Damien Galanaud²⁵, Guoyi Gao⁷⁴, Karin Geleijns⁴¹, Alexandre Ghuyssen⁷⁵, Benoit Giraud²⁴, Ben Glocker⁷⁶, Pedro A. Gomez⁴², Francesca Grossi⁵⁹, Russell L. Gruen⁷⁷, Deepak Gupta⁷⁸, Juanita A. Haagsma⁴⁶, Ermin Hadzic⁶⁴, Iain Haitsma⁷⁹, Jed A. Hartings⁸⁰, Raimund Helbok²¹, Erik Helseth⁸¹, Daniel Hertle²⁸, Sean Hill⁸², Astrid Hoedemaekers⁸³, Stefan Hoefler⁵¹, Peter J. Hutchinson¹, Kristine Asta Håberg⁸⁴, Bram Jacobs⁸⁵, Ivan Janciak⁸⁶, Koen Janssens⁵⁸, Ji-yao Jiang⁷⁴, Kelly Jones⁸⁷, Jean-Pierre Kalala⁸⁸, Konstantinos Kamnitsas⁷⁶, Mladen Karan⁸⁹, Jana Karau²⁰, Ari Katila⁶⁹, Maija Kaukonen⁹⁰, David Keeling⁵², Thomas Kerforne²⁴, Naomi Ketharanathan⁴¹, Johannes Kettunen⁹¹, Riku Kivisaari⁹⁰, Angelos G. Kolias¹, Bálint Kolumbán⁹², Erwin Kompanje⁹³, Daniel Kondziella⁶⁷, Lars-Owe Koskinen³⁵, Noémi Kovács⁹², Ferenc Kálóvits⁹⁴, Alfonso Lagares⁶⁴, Linda Lanyon⁸², Steven Laureys⁹⁵, Martin Lauritzen⁶⁷, Fiona Lecky⁹⁶, Christian Ledig⁷⁶, Rolf Lefering⁹⁷, Valerie Legrand⁹⁸, Jin Lei⁶¹, Leon Levi⁹⁹, Roger Lightfoot¹⁰⁰, Hester Lingsma⁴⁶, Dirk Loeckx¹⁰¹, Angels Lozano¹⁰⁶, Roger Luddington¹⁷, Chantal Luijten-Arts⁸³, Andrew I.R. Maas⁵⁸, Stephen MacDonald¹⁷, Charles MacFayden⁶⁵, Marc Maegele¹⁰², Marek Majdan³³, Sebastian Major¹⁰³, Alex Manara¹⁰⁴, Pauline Manhes³¹, Geoffrey Manley¹⁰⁵, Didier Martin¹⁰⁶, Costanza Martino², Armando Maruenda¹⁶, Hugues Maréchal⁵⁵, Dagmara Mastelova⁸⁶, Julia Mattern²⁸, Catherine McMahon¹⁰⁷, Béla Melegh¹⁰⁸, David Menon⁶⁵, Tomas Menovsky⁵⁸, Cristina Morganti-Kossmann¹⁰⁹, Davide Mulazzi³⁸, Manuel Mutschler¹⁰², Holger Mühlhan¹¹⁰, Ancuta Negru¹¹¹, David Nelson⁸², Eddy Neugebauer¹⁰², Virginia Newcombe⁶⁵, Quentin Noirhomme⁹⁵, József Nyírádi⁴, Mauro Oddo¹¹², Annemarie Oldenbeuving¹¹³, Matej Oresic¹¹⁴, Fabrizio Ortolano³⁸, Aarno Palotie^{91, 115, 116}, Paul M. Parizel¹¹⁷, Adriana Patrino¹¹⁸, Jean-François Payen³¹, Natascha Perera¹¹⁹, Vincent Perlbarg²⁵, Paolo Persona¹²⁰, Wilco Peul¹²¹, Nicolas Pichon¹²², Henning Piilgaard⁶⁷, Anna Piippo⁹⁰, Sébastien Pili Floury¹²³, Matti Pirinen⁹¹, Horia Ples¹¹¹, Suzanne Polinder⁴⁶, Inigo Pomposo⁴⁰, Marek Psota³³, Pim Pullens¹¹⁷, Louis Puybasset¹²⁴, Arminas Ragauskas¹²⁵, Rahul Raj⁹⁰, Malinka Rambadagalla¹²⁶, Veronika Rehorčíková³³, Jonathan Rhodes¹²⁷, Sylvia Richardson¹²⁸, Samuli Ripatti⁹¹, Saulius Rocka¹²⁵, Nicolas Rodier¹²², Cecile Roe¹²⁹, Olav Roise¹³⁰, Gerwin Roks¹³¹, Pauline Romegoux³¹, Jonathan Rosand¹³², Jeffrey Rosenfeld¹⁰⁹, Christina Rosenlund³³, Guy Rosenthal⁷², Rolf Rossaint⁴⁷, Sandra Rossi¹²⁰, Tim Rostalski¹¹⁰, Daniel Rueckert⁷⁶, Arcaute Felix de Ruiz¹⁰¹, Martin Rusnák⁸⁶, Marco Sacchi¹⁴, Barbara Sahakian⁶⁵, Juan Sahuquillo¹³⁴, Oliver Sakowitz^{135, 136}, Francesca Sala¹¹⁸, Paola Sanchez-Pena²⁵, Renan Sanchez-Porras^{28, 135}, Janos Sandor¹³⁷, Edgar Santos²⁸, Nadine Sasse⁵¹, Luminita Sasu⁵⁹, Davide Savo¹¹⁸, Inger Schipper¹³⁸, Barbara Schläßer²⁰, Silke Schmidt¹¹⁰, Annette Schneider⁶⁷, Herbert Schoechl¹³⁹, Guus Schoonman¹³¹, Frederik Schou Rico¹⁴⁰, Elisabeth Schwendenwein⁹, Michael Schöhl²⁸, Özcan Sir¹⁴¹, Toril Skandsen¹⁴², Ludwien Smakman¹⁴³, Dirk Smeets¹⁰¹, Peter Smielewski⁵⁴, Abayomi Sorinola¹⁴⁴, Emmanuel Stamatakis⁶⁵, Simon Stanworth⁵², Katrin Stegemann¹¹⁰, Nicole Steinbüchel¹⁴⁵, Robert Stevens¹⁴⁶, William Stewart¹⁴⁷, Ewout W. Steyerberg⁴⁶, Nino Stocchetti¹⁴⁸, Nina Sundström³⁵, Anneliese Synnot^{149, 150}, József Szabó³⁴, Jeannette Söderberg⁸², Fabio Silvio Taccone¹⁶, Viktória Tamás¹⁴⁴, Päivi Tanskanen⁹⁰, Alexandru Tascu³⁴, Mark Steven Taylor³³, Ao Braden Te⁶⁸, Olli Tenovuuo⁶⁹, Guido Teodorani¹⁵¹, Alice Theadom⁶⁸, Matt Thomas¹⁰⁴, Dick Tibboel⁴¹, Christos Tolia¹⁵², Jean-Flory Luaba Tshibanda¹⁵³, Cristina Maria Tudora¹¹¹, Peter Vajkoczy¹⁵⁴, Egils Valeinis¹⁵⁵, Wim Van Hecke¹⁰¹, Dominique Van Praag⁵⁸, Van Roost Dirk⁸⁸, Eline Van Vierberghe¹⁰¹, Thijs vande Vyvere¹⁰¹, Audrey Vanhauzenhuyse^{25, 95}, Alessia Vargiolu¹¹⁸, Emmanuel Vega¹⁵⁶, Jan Verheyden¹⁰¹, Paul M. Vespa¹⁵⁷, Anne Vik¹⁵⁸, Rimantas Vilcinis¹⁵⁹, Giacinta Vizzino¹⁴, Carmen Vleggeert-Lankamp¹⁴³, Victor Volovici⁷⁹, Peter Vulekovic⁸⁹, Zoltán Vámos⁶⁶, Derick Wade⁵⁷, Kevin K.W. Wang¹⁶⁰, Lei Wang⁶¹, Eno Wildschut⁴¹, Guy Williams⁶⁵, Lisette Willumsen⁶⁷, Adam Wilson⁵, Lindsay Wilson¹⁶¹, Maren K.L. Winkler¹⁰³, Peter Ylén¹⁶², Alexander Younsi²⁸, Menashe Zaarou⁹⁹, Zhiqun Zhang¹⁶³, Zelong Zheng²⁸, Fabrizio Zumbo², Stefanie de Lange⁹⁷, Godard C.W. de Ruitter¹⁴³, Hugo den Boogert¹⁸, Jeroen van Dijk¹⁶⁴, Thomas A. van Essen¹²¹, Caroline van Heugten⁵⁷, Mathieu van der Jagt¹⁶⁵, Joukje van der Naalt⁸⁵¹

Affiliations

¹ Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

² Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy

³ Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

⁴ János Szentágotthai Research Centre, University of Pécs, Pécs, Hungary

⁵ University of Cincinnati, Cincinnati, OH, United States

⁶ Division of Surgery and Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway

⁷ Department of Neurosurgery, University Hospital of Northern Norway, Tromsø, Norway

⁸ Department of Physical Medicine and Rehabilitation, University Hospital of Northern Norway, Tromsø, Norway

⁹ Trauma Surgery, Medical University Vienna, Vienna, Austria

¹⁰ Department of Neurosurgery, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands

¹¹ Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France

¹² Riga Eastern Clinical University Hospital, Riga, Latvia

¹³ Raymond Poincaré Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France

¹⁴ Neurointensive Care, Niguarda Hospital, Milan, Italy

¹⁵ Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

¹⁶ Department of Anesthesiology and Surgical-Trauma Intensive Care, Hospital Clinic Universitari de Valencia, Valencia, Spain

¹⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

¹⁸ Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands

¹⁹ Department of Neurosurgery, University of Szeged, Szeged, Hungary

²⁰ Institute for Transfusion Medicine (ITM), Witten/Herdecke University, Cologne, Germany

²¹ Department of Neurocritical Care, Innsbruck Medical University, Innsbruck, Austria

²² Department of Neurosurgery & Anesthesia & Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden

²³ NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK

²⁴ Intensive Care Unit, CHU Poitiers, Poitiers, France

²⁵ Anesthésie-Réanimation, Assistance Publique – Hôpitaux de Paris, Paris, France

²⁶ Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy

²⁷ Department of Anesthesiology & Intensive Care, S. Raffaele University Hospital, Milan, Italy

²⁸ Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany

²⁹ Department of Neurology, Odense University Hospital, Odense, Denmark

³⁰ Departments of Neuroscience and Nursing Science, Norwegian University of Science and Technology, Trondheim, Norway

³¹ Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France

³² BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Clayton, Australia

³³ Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia

³⁴ Department of Neurosurgery, Bagdasar-Arseni Emergency Clinical Hospital, Bucharest, Romania

³⁵ Department of Neurosurgery, Umeå University Hospital, Umeå, Sweden

³⁶ Department of Neurosurgery, University of Pécs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentágotthai Research Centre, University of Pécs, and Hungarian Brain Research Program, Pécs, Hungary

³⁷ Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

³⁸ Neuro-ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

³⁹ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

⁴⁰ Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain

⁴¹ Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands

⁴² Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

- ⁴³ Department of Neuroscience, Azienda Ospedaliera Università di Padova, Padua, Italy
- ⁴⁴ Neurointensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
- ⁴⁵ School of Medicine and Surgery, Università Milano Bicocca, Milan, Italy
- ⁴⁶ Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands
- ⁴⁷ Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- ⁴⁸ Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- ⁴⁹ School of Public Health and Preventive Medicine, Monash University and The Alfred Hospital, Melbourne, Australia
- ⁵⁰ Radiology/MRI Department, MRC Cognition and Brain Sciences Unit, Cambridge, UK
- ⁵¹ Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany
- ⁵² Oxford University Hospitals NHS Trust, Oxford, UK
- ⁵³ Department of Neurosurgery, University of Pécs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pécs, and Hungarian Brain Research Program (grant KTIA 13 NAP-A-II/8), Pécs, Hungary
- ⁵⁴ Brain Physics Lab, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- ⁵⁵ Intensive Care Unit, CHR Citadelle, Liège, Belgium
- ⁵⁶ Intensive Care Unit, CHU de Liège, Liège, Belgium
- ⁵⁷ Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
- ⁵⁸ Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
- ⁵⁹ Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy
- ⁶⁰ Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- ⁶¹ Department of Neurosurgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- ⁶² Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands
- ⁶³ Department of Neurosurgery, Medical Faculty and Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
- ⁶⁴ Department of Neurosurgery, Regional Medical Center dr Safet Mujčić, Mostar, Bosnia and Herzegovina
- ⁶⁵ Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- ⁶⁶ Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary
- ⁶⁷ Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
- ⁶⁸ National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, NZ
- ⁶⁹ Rehabilitation and Brain Trauma, Turku University Central Hospital and University of Turku, Turku, Finland
- ⁷⁰ Department of Medicine, Azienda Ospedaliera Università di Padova, Padua, Italy
- ⁷¹ Department of Anesthesiology and Intensive Care, University Hospital of Northern Norway, Tromsø, Norway
- ⁷² Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- ⁷³ Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain
- ⁷⁴ Department of Neurosurgery, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- ⁷⁵ Emergency Department, CHU de Liège, Liège, Belgium
- ⁷⁶ Department of Computing, Imperial College London, London, UK
- ⁷⁷ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and Monash University, Clayton, Australia
- ⁷⁸ Department of Neurosurgery, Neurosciences Centre & JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
- ⁷⁹ Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
- ⁸⁰ Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA
- ⁸¹ Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- ⁸² Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden
- ⁸³ Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- ⁸⁴ Department of Medical Imaging, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
- ⁸⁵ Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands
- ⁸⁶ International Neurotrauma Research Organisation, Vienna, Austria
- ⁸⁷ National Institute for Stroke & Applied Neurosciences, Auckland University of Technology, Auckland, NZ
- ⁸⁸ Department of Neurosurgery, University Hospital Ghent, Ghent, Belgium
- ⁸⁹ Department of Neurosurgery, Clinical Centre of Vojvodina, Novi Sad, Serbia
- ⁹⁰ Helsinki University Central Hospital, Helsinki, Finland
- ⁹¹ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- ⁹² Hungarian Brain Research Program (grant KTIA 13 NAP-A-II/8), University of Pécs, Pécs, Hungary
- ⁹³ Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- ⁹⁴ Department of Neurological & Spinal Surgery, Markusovszky University Teaching Hospital, Szombathely, Hungary
- ⁹⁵ Cyclotron Research Center, University of Liège, Liège, Belgium
- ⁹⁶ Emergency Medicine Research in Sheffield, Health Services Research Section, School of Health and Related Research (SchHARR), University of Sheffield, Sheffield, UK
- ⁹⁷ Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany
- ⁹⁸ VP Global Project Management, Central Nervous System, ICON plc, Paris, France
- ⁹⁹ Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- ¹⁰⁰ Department of Anesthesiology & Intensive Care, University Hospitals Southampton NHS Trust, Southampton, UK
- ¹⁰¹ icoMetrix NV, Leuven, Belgium
- ¹⁰² Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sports Medicine, Witten/Herdecke University, Cologne, Germany
- ¹⁰³ Centrum für Schlaganfallforschung, Charité – Universitätsmedizin Berlin, Berlin, Germany
- ¹⁰⁴ Intensive Care Unit, Southmead Hospital Bristol, Bristol, UK
- ¹⁰⁵ Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
- ¹⁰⁶ Department of Neurosurgery, CHU de Liège, Liège, Belgium
- ¹⁰⁷ Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- ¹⁰⁸ Department of Medical Genetics, University of Pécs, Pécs, Hungary
- ¹⁰⁹ National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Australia
- ¹¹⁰ Department Health and Prevention, University Greifswald, Greifswald, Germany
- ¹¹¹ Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania
- ¹¹² Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- ¹¹³ Department of Intensive Care, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands
- ¹¹⁴ Department of Systems Medicine, Steno Diabetes Center, Gentofte, Denmark
- ¹¹⁵ Analytic and Translational Genetics Unit, Department of Medicine, Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- ¹¹⁶ Program in Medical and Population Genetics, The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- ¹¹⁷ Department of Radiology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
- ¹¹⁸ Neurointensive Care Unit, Department of Anesthesia & Intensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
- ¹¹⁹ International Projects Management, ARTTIC, Munich, Germany
- ¹²⁰ Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padua, Italy

¹²¹ Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Department of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands

¹²² Intensive Care Unit, CHU Dupuytren, Limoges, France

¹²³ Intensive Care Unit, CHRU de Besançon, Besançon, France

¹²⁴ Department of Anesthesiology and Critical Care, Pitié-Salpêtrière Teaching Hospital, Assistance Publique – Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France

¹²⁵ Department of Neurosurgery, Kaunas University of Technology and Vilnius University, Vilnius, Lithuania

¹²⁶ Rēzekne Hospital, Rēzekne, Latvia

¹²⁷ Department of Anaesthesia, Critical Care & Pain Medicine, NHS Lothian & University of Edinburgh, Edinburgh, UK

¹²⁸ Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK

¹²⁹ Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway

¹³⁰ Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

¹³¹ Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands

¹³² The Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA

¹³³ Department of Neurosurgery, Odense University Hospital, Odense, Denmark

¹³⁴ Department of Neurosurgery, Vall d'Hebron University Hospital, Barcelona, Spain

¹³⁵ Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany

¹³⁶ University Hospital Heidelberg, Heidelberg, Germany

¹³⁷ Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary

¹³⁸ Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands

¹³⁹ Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria

¹⁴⁰ Department of Neuroanaesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark

¹⁴¹ Department of Emergency Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

¹⁴² Department of Physical Medicine and Rehabilitation, St. Olavs Hospital and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

¹⁴³ Neurosurgical Cooperative Holland, Department of Neurosurgery, Leiden University Medical Center and Medical Center Haaglanden, Leiden and The Hague, The Netherlands

¹⁴⁴ Department of Neurosurgery, University of Pécs, Pécs, Hungary

¹⁴⁵ Universitätsmedizin Göttingen, Göttingen, Germany

¹⁴⁶ Division of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹⁴⁷ Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK

¹⁴⁸ Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

¹⁴⁹ Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

¹⁵⁰ Cochrane Consumers and Communication Review Group, Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne, Australia

¹⁵¹ Department of Rehabilitation, M. Bufalini Hospital, Cesena, Italy

¹⁵² Department of Neurosurgery, King's College London, London, UK

¹⁵³ Radiology/MRI Department, CHU de Liège, Liège, Belgium

¹⁵⁴ Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin, Berlin, Germany

¹⁵⁵ Pauls Stradiņš Clinical University Hospital, Riga, Latvia

¹⁵⁶ Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France

¹⁵⁷ Director of Neurocritical Care, University of California, Los Angeles, Los Angeles, CA, USA

¹⁵⁸ Department of Neurosurgery, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

¹⁵⁹ Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania

¹⁶⁰ Department of Psychiatry, University of Florida, Gainesville, FL, USA

¹⁶¹ Division of Psychology, University of Stirling, Stirling, UK

¹⁶² VTT Technical Research Centre, Tampere, Finland

¹⁶³ University of Florida, Gainesville, FL, USA

¹⁶⁴ Department of Neurosurgery, The Haga Hospital, The Hague, The Netherlands

¹⁶⁵ Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands

Funding

Data used in the preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission Seventh Framework program (602150). In addition, TvE and WCP were supported by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study.

Availability of data and materials

The datasets analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

MCC analyzed the data and wrote the manuscript. JAH designed Fig. 2a and b. MCC, MvdJ, W, TvE, SP, DN, AE, NS, GC, WCP, AIRM, DM, EWS, and HFL were involved in the development of the provider profiling questionnaires. All authors critically commented on the manuscript, and all authors read and approved the final version.

Ethics approval and consent to participate

Not applicable. There are no patients included in present study, and participating centers have given consent by completing the questionnaires.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Center for Medical Decision Making, Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. ²Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands. ³Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands. ⁴Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands. ⁵Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden. ⁶Division of Anesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ⁷Department of Pathophysiology and Transplants, University of Milan, Milan, Italy. ⁸Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Department of Anesthesia and Critical Care, Neuroscience Intensive Care Unit, Milan, Italy. ⁹School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. ¹⁰Neurointensive Care Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy. ¹¹Department of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands. ¹²Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium. ¹³Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.

Received: 22 May 2017 Accepted: 10 August 2017

Published online: 06 September 2017

References

- Balestreri M, Czosnyka M, Hutchinson P, Steiner LA, Hiler M, Smielewski P, Pickard JD. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. *Neurocrit Care*. 2006;4(1):8–13.
- Maas AI, Menon DK, Lingsma HF, Pineda JA, Sandel ME, Manley GT. Re-orientation of clinical research in traumatic brain injury: report of an international workshop on comparative effectiveness research. *J Neurotrauma*. 2012;29(1):32–46.
- Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, Gruen RL. A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. *J Neurotrauma*. 2016;33(16):1461–78.
- Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. *Am J Ther*. 2002;9(3):199–205.
- Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol*. 2010;63(1):64–74.
- Sharma S, Gomez D, de Mestral C, Hsiao M, Rutka J, Nathens AB. Emergency access to neurosurgical care for patients with traumatic brain injury. *J Am Coll Surg*. 2014;218(1):51–7.
- Skoglund K, Enblad P, Marklund N. Monitoring and sedation differences in the management of severe head injury and subarachnoid hemorrhage among neurocritical care centers. *J Neurosci Nurs*. 2013;45(6):360–8.
- Cnossen MC, Polinder S, Andriessen TM, van der Naalt J, Haitsma I, Horn J, Franschman G, Vos PE, Steyerberg EW, Lingsma H. Causes and consequences of treatment variation in moderate and severe traumatic brain injury: a multicenter study. *Crit Care Med*. 2017;45(4):660–9.
- van Essen TA, de Ruyter GC, Kho KH, Peul WC. Neurosurgical treatment variation of traumatic brain injury: evaluation of acute subdural hematoma management in Belgium and The Netherlands. *J Neurotrauma*. 2017;34(4):881–9.
- Maas AI, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, Hill S, Legrand V, Sorgner A, Participants CT, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. *Neurosurgery*. 2015;76(1):67–80.
- Timmons SD, Toms SA. Comparative effectiveness research in neurotrauma. *Neurosurg Focus*. 2012;33(1):E3.
- Stocchetti N, Penny KI, Dearden M, Braakman R, Cohadon F, Iannotti F, Lapiere F, Karimi A, Maas Jr A, Murray GD, et al. Intensive care management of head-injured patients in Europe: a survey from the European brain injury consortium. *Intensive Care Med*. 2001;27(2):400–6.
- Enblad P, Nilsson P, Chambers I, Citerio G, Fiddes H, Howells T, Kiening K, Ragauskas A, Sahuquillo J, Yau YH, et al. R3-Survey of traumatic brain injury management in European brain IT centres year 2001. *Intensive Care Med*. 2004;30(6):1058–65.
- Cnossen MC, Polinder S, Lingsma HF, Maas AI, Menon D, Steyerberg EW, Investigators C-T, Participants. Variation in structure and process of care in traumatic brain injury: provider profiles of European neurotrauma centers participating in the CENTER-TBI study. *PLoS One*. 2016;11(8):e0161367.
- Hesdorffer DC, Ghajar J. Marked improvement in adherence to traumatic brain injury guidelines in United States trauma centers. *J Trauma*. 2007;63(4):841–8.
- Zuercher P, Groen JL, Aries MJ, Steyerberg EW, Maas AI, Ercole A, Menon DK. Reliability and Validity of the Therapy Intensity Level Scale: analysis of clinimetric properties of a novel approach to assess management of intracranial pressure in traumatic brain injury. *J Neurotrauma*. 2016;33(19):1768–74.
- IBM Corporation. IBM SPSS Statistics for Windows version 21.0 software. Armonk, NY: IBM; 2012.
- Nathens AB, Rivara FP, MacKenzie EJ, Maier RV, Wang J, Egleston B, Scharfstein DO, Jurkovich GJ. The impact of an intensivist-model ICU on trauma-related mortality. *Ann Surg*. 2006;244(4):545–54.
- Thomas L, Cullum N, McColl E, Rousseau N, Soutter J, Steen N. Guidelines in professions allied to medicine. *Cochrane Database Syst Rev*. 2000;2:CD000349.
- Brain Trauma Foundation, American Association of Neurological Surgeon, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. *J Neurotrauma*. 2007;24 Suppl 1:S1–106.
- European Commission. The social situation in the European Union 2007. Luxembourg: Office for Official Publications of the European Union; 2007. p. 1–220.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

